Organoidsciences KRX:476040KOSDAQ
오가노이드사이언스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days4
DART filings, 7 days0
Articles tracked29since Sep 11
In Q2 2026, Organoidsciences reported revenue of ₩598m, down 1.1% year on year, and an operating loss of ₩4.4bn. Organoidsciences (오가노이드사이언스) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 27 with 4 articles.
Filing signals 4 quarters of losses Screener
Organoidsciences quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩598m | -1.1% | −₩4.4bn | −₩7.0bn |
| Q1 2026 | ₩144m | -43.6% | −₩4.2bn | −₩4.4bn |
| Q4 2025 derived | ₩1.2bn | -10.2% | −₩3.8bn | −₩3.6bn |
| Q3 2025 | ₩320m | +8.4% | −₩3.9bn | −₩3.9bn |
| Q2 2025 | ₩605m | +187.9% | −₩4.7bn | −₩4.5bn |
| Q1 2025 | ₩255m | – | −₩3.8bn | −₩3.7bn |
| Q4 2024 derived | ₩1.4bn | – | −₩2.1bn margin −155.4% | −₩2.1bn |
| Q3 2024 | ₩295m | – | −₩3.4bn | −₩3.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Organoidsciences top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest Organoidsciences news Korean headlines
-
오가노이드사이언스, 베트남 국립대와 협력...동남아 사업 기반 확대
3 more on this story · 3 outlets
- 오가노이드사이언스, 베트남 바이오 명문대와 협력…동남아 사업 확대전자신문 · Oct 14 10:26
- 오가노이드사이언스, 베트남 국립대와 협력…동남아 사업 확대뉴스1 · Oct 14 15:12
- 오가노이드사이언스, 베트남 HUS와 협력 … 동남아 사업기반 확대뉴데일리경제 · Oct 14 15:33
-
오가노이드사이언스, 美 CGT 행사서 NAMs·재생치료제 발표
4 more on this story · 4 outlets
- 오가노이드사이언스, 美 행사서 NAMs·재생치료제 발표메디포뉴스 · Oct 7 09:20
- 오가노이드사이언스, 美 CGT 행사서 재생치료제 임상 성과 공개…NAMs 사업 확대한국경제 · Oct 7 10:59
- 오가노이드사이언스, 美 CGT 행사서 NAMs∙재생치료제 개발 전략 발표바이오타임즈 · Oct 7 12:47
- 오가노이드사이언스, 美 CGT 무대서 NAMs·재생치료제 잇단 발표뉴스1 · Oct 7 16:17